Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

StockMarketGuru Jun. 29 at 10:33 PM

$CRSP $NTLA $PRME Interest is at its highest point ever, nearing a peak score of 100 (Google’s maximum search interest)

0 · Reply

architheia Jun. 29 at 1:32 AM

$PRME pumping.

0 · Reply

inflect1on Jun. 27 at 6:39 PM

$PRME some stops hit between 2.4–2.5 ehh should’ve timed the exit manually, holding core but some retrace was expected

2 · Reply

_www_larval_com_ Jun. 27 at 2:37 PM

$PRME has sunk -7% lower to -4% (~708Kv) a moment ago, 07/18 options, follow for more volatility.

0 · Reply

babarsiddiqui56 Jun. 27 at 12:20 PM

$BBLG this is running!! $PRME $CYN

0 · Reply

Abetwit Jun. 27 at 5:12 AM

$NTLA $PRME $CRSP $BEAM Finally at a profit on Prime. Intellia and Crisper at break even. If fundamentals are intact you just have to DCA, even when down 80%.

1 · Reply

LadsAndGents Jun. 26 at 11:46 PM

$PRME I hardly post these things at this platform but happy with Prime

1 · Reply

mankind1 Jun. 26 at 9:09 PM

$PRME interesting rise here.

0 · Reply

johnnygogogo Jun. 26 at 7:55 PM

$PRME my cost basis is approx the same as the recent open market buys from the founder of the company. Small position but gonna hold until I see him sell. Keeping it simple. Also, know full well that a secondary could be in the works, but so could a lot of other things.

0 · Reply

angelinvesting369 Jun. 26 at 7:54 PM

$PRME $VRTX makes $11B/yr w their cystic fibrosis treatment. David Liu has his 🎯. Prime is the next $PLTR iykyk https://medicalxpress.com/news/2024-07-prime-efficiently-cystic-fibrosis-mutation.html

2 · Reply

Prime Medicine to Participate in Upcoming Investor Conferences

May 19, 2025, 8:31 AM EDT - 5 weeks ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 5 weeks ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 7 weeks ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 3 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 4 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 4 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 5 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 7 months ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 7 months ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 8 months ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 9 months ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 9 months ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 9 months ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 9 months ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 4:05 PM EST - 1 year ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jan 28, 2024, 8:11 AM EST - 1 year ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 1 year ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 2, 2024, 8:00 AM EST - 1 year ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 2:45 PM EST - 1 year ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

Nov 8, 2023, 8:00 AM EST - 1 year ago

Prime Medicine to Present at Upcoming Investor Conferences

Nov 3, 2023, 4:01 PM EDT - 1 year ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 27, 2023, 6:00 AM EDT - 1 year ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Sep 27, 2023, 8:49 AM EDT - 1 year ago

Prime Medicine: Not Yet Primed For Retail Investment

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

May 31, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at Investor Conferences in June

May 17, 2023, 4:05 PM EDT - 2 years ago

Prime Medicine to Present at Virtual Investor Conferences in May

May 17, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

May 11, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 23, 2023, 9:10 AM EDT - 2 years ago

Prime Medicine: Gene Editing Tech With Unique Approach

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

Mar 9, 2023, 8:00 AM EST - 2 years ago

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 27, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Cowen 43rd Annual Health Care Conference

Jan 12, 2023, 12:15 AM EST - 2 years ago

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

CRSP

Jan 4, 2023, 11:04 AM EST - 2 years ago

10 Potential 10x Return Stocks For The Next 10 Years

ABCL ASTS BEAM CRSP EDIT FROG HCP

Jan 3, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference

StockMarketGuru Jun. 29 at 10:33 PM

$CRSP $NTLA $PRME Interest is at its highest point ever, nearing a peak score of 100 (Google’s maximum search interest)

0 · Reply

architheia Jun. 29 at 1:32 AM

$PRME pumping.

0 · Reply

inflect1on Jun. 27 at 6:39 PM

$PRME some stops hit between 2.4–2.5 ehh should’ve timed the exit manually, holding core but some retrace was expected

2 · Reply

_www_larval_com_ Jun. 27 at 2:37 PM

$PRME has sunk -7% lower to -4% (~708Kv) a moment ago, 07/18 options, follow for more volatility.

0 · Reply

babarsiddiqui56 Jun. 27 at 12:20 PM

$BBLG this is running!! $PRME $CYN

0 · Reply

Abetwit Jun. 27 at 5:12 AM

$NTLA $PRME $CRSP $BEAM Finally at a profit on Prime. Intellia and Crisper at break even. If fundamentals are intact you just have to DCA, even when down 80%.

1 · Reply

LadsAndGents Jun. 26 at 11:46 PM

$PRME I hardly post these things at this platform but happy with Prime

1 · Reply

mankind1 Jun. 26 at 9:09 PM

$PRME interesting rise here.

0 · Reply

johnnygogogo Jun. 26 at 7:55 PM

0 · Reply

angelinvesting369 Jun. 26 at 7:54 PM

2 · Reply

stuntman9883 Jun. 26 at 5:43 PM

$PRME https://youtu.be/uh-2IBC_AP0?si=9kEZCPF_Yjc7qgqU time to sell

0 · Reply

mcnulty2002 Jun. 26 at 3:49 PM

$PRME I wish I had bought an irresponsible amount of this. Another lesson in time in the market > timing the market. When will I learn. Good news is, it is still insanely early here

3 · Reply

angelinvesting369 Jun. 26 at 3:42 PM

$ALT $PLTR $PRME 👀 headed to $3 on the way to $10 $VERV $LLY deal set the floor at $1B

0 · Reply

angelinvesting369 Jun. 26 at 3:12 PM

$ALT investing in bs like alt while the most advanced technology company $PRME since $PLTR is still on sale is not prudent https://youtube.com/shorts/bm8olKRr-6o?si=KKI26LZrd00SyNVs

0 · Reply